CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1472-1478

  Hertz, D L ^a   Roy, S ^b   Motsinger Reif, A A ^a,b   Drobish, A ^c   Clark, L S ^d   McLeod, H L ^a,c,e   Carey, L A ^c,e   Dees, E C ^c,e  

^a University of North Carolina   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Gentris Corporation   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy induced peripheral neuropathy; Cytochrome P450 2C8*3; Paclitaxel; Pharmacogenetics; Race

Indexed keywords

AMITRIPTYLINE; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C8; DOCETAXEL; DOXORUBICIN; GABAPENTIN; GLUTAMINE; LAPATINIB; PACLITAXEL; PYRIDOXINE; TRASTUZUMAB; VITAMIN B COMPLEX; ANTINEOPLASTIC AGENT; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; EUROPEAN AMERICAN; GENOTYPE; HEALTH STATUS; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; PRIORITY JOURNAL; RACE DIFFERENCE; BREAST TUMOR; CAUCASIAN; CHEMICALLY INDUCED DISORDER; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CYTOCHROME P450 2C8*3; ENZYMOLOGY; FEMALE; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PARANEOPLASTIC NEUROPATHY; PHARMACOGENETICS; RACE; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CYTOCHROME P450 2C8*3; PACLITAXEL; PHARMACOGENETICS; RACE;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; PACLITAXEL; PARANEOPLASTIC POLYNEUROPATHY; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875940168     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt018     Document Type: Article

References (35)

1. Gines J, Sabater E, Martorell C et al Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol 2011; 13(7): 485-498.
2. Mamounas EP, Bryant J, Lembersky B et al Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23(16): 3686-3696.
3. Citron ML, Berry DA, Cirrincione C et al Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003; 21(8): 1431-1439.
4. Postma TJ, Vermorken JB, Liefting AJM et al Paclitaxel-induced neuropathy. Ann Oncol 1995; 6(5): 489-494.
5. Rowinsky EK, Chaudhry V, Cornblath DR et al Neurotoxicity of taxol. J Natl Cancer Inst Monogr 1993; 1993(15): 107-115.
6. Rowinsky EK, Eisenhauer EA, Chaudhry V et al Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 1993; 20(4 Suppl. 3): 1-15.
7. Akerley W, Herndon JE, Egorin MJ et al Weekly, high-dose paclitaxel in advanced lung carcinoma. Cancer 2003; 97(10): 2480-2486.
8. Schneider BP, Zhao F, Wang M et al Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012; 30(25): 3051-3057.
9. Mielke S, Mross K, Gerds TA et al Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003; 14(10): 785-792.
10. Mielke S, Sparreboom A, Steinberg SM et al Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11(13): 4843-4850.
11. Rahman A, Korzekwa KR, Grogan J et al Selective biotransformation of taxol to 6 {alpha}-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54 (21): 5543-5546.
12. Harris JW, Rahman A, Kim B et al Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54(15): 4026-4035.
13. Hertz DL, Walko CM, Bridges AS et al Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol 2012; 74(1): 197-200.
14. Henningsson A, Sparreboom A, Sandström M et al Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003; 39(8): 1105-1114.
15. Rowbotham SE, Boddy AV, Redfern CPF et al Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 2010; 38(8): 1261-1266.
16. Bergmann TK, Brasch-Andersen C, Green H et al Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11(2): 113-120.
17. International HapMap Project frequency report for refSNP rs10509681 [Internet] 2005; http://hapmap.ncbi.nlm.nih.gov/cgi-perl/snp_details_phase3? name=rs10509681&source=hapmap28_B36&tmpl=snp_details_phase3.
18. The International HapMap Project. Nature 2003; 426(6968): 789-796.
19. Gréen H, Söderkvist P, Rosenberg P et al Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009; 104(2): 130-137.
20. Hertz DL, Motsinger-Reif AA, Drobish A et al CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012; 134(1): 401-410.
21. Leskela S, Jara C, Leandro-Garcia L et al Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011; 11(2): 121-129.
22. Common terminology criteria for adverse events (CTCAE) version 4.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute 2010.
23. Li W, Nyholt DR. Marker selection by Akaike information criterion and Bayesian information criterion. Genet Epidemiol 2001; 21(Suppl. 1): S272-S277.
24. Barnholtz-Sloan JS, de Andrade M, Chakraborty R. The impact of population admixture on traditional linkage analysis. Ethn Dis 2001; 11(3): 519-531.
25. Sanderson S, Zimmern R, Kroese M et al How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005; 7(7): 495-500.
26. Rizzo R, Spaggiari F, Indelli M et al Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010; 124(2): 593-598.
27. Marsh S, Paul J, King CR et al Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 2007; 25(29): 4528-4535.
28. Bergmann TK, Gréen H, Brasch-Andersen C et al Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67(7): 693-700.
29. Bergmann TK, Brasch-Andersen C, Gréen H et al Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 2012; 110(2): 199-204.
30. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011: doi: 10.1155/2011/843019.
31. Tayo BO, Teil M, Tong L et al Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine. PLoS ONE 2011; 6(5): e19166.
32. Schneider BP, Li L, Miller K et al Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstracts 2011; 29(15 Suppl.): 1000.
33. Anziska Y, Helzner EP, Crystal H et al The relationship between race and HIVdistal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 2012; 315(1-2): 129-132.
34. Soderstrom LH, Johnson SP, Diaz VA et al Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001- 2004 NHANES. Diabetic Med 2012; 29(1): 50-55.
35. Huang T, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012; 38(6): 613-617.